不同重度与晚期心衰定义在瑞典心衰注册中的真实世界预后表现
基于瑞典心衰注册中15153例EF<40%、心衰病程>6个月且无LVAD或移植史的患者,评估多种重度/晚期心衰定义的患病率与预后表现。HFA定义识别6.4%患者,1年心血管死亡/心衰住院风险70%、全因死亡45%(AUC=0.72);GALACTIC-Severe定义识别12.6%患者,对应事件率59%和38%(AUC=0.73);加入NT-proBNP≥2000 pg/ml的定义预后准确性最高(AUC=0.75)。
要点
- HFA-AdvHF定义筛选出较小的高危人群,1年事件率更高。
- GALACTIC-Severe定义覆盖更广人群,事件率略低但仍较高。
- NT-proBNP、心衰住院史和利尿剂剂量或可用于未来试验富集。
核心结论
- HFA-AdvHF定义筛选出较小的高危群体,而GALACTIC-Severe标准识别更广泛人群、风险略低但仍高。
- NT-proBNP、心衰住院史和利尿剂剂量可能是未来试验的有价值富集工具。
研究设计与样本
- 基于瑞典心衰注册的回顾性队列分析,纳入15153例EF<40%、心衰病程>6个月且无既往LVAD或心脏移植的患者。
- 评估多种重度/晚期心衰定义:简化HFA定义(NYHA III-IV、EF<30%、12个月内≥2次心衰住院)、GALACTIC-Severe定义(NYHA III-IV、EF<30%、6个月内≥1次住院),以及在HFA-AdvHF定义上增加/移除NT-proBNP水平和利尿剂剂量等标准的变体。
- 分析预测性能和1年结局。
主要发现
- HFA定义识别6.4%的患者,1年心血管死亡/心衰住院风险为70%,全因死亡率为45%(AUC=0.72)。
- GALACTIC-Severe定义识别12.6%的患者,1年心血管死亡/心衰住院风险为59%,全因死亡率为38%(AUC=0.73)。
- 纳入NT-proBNP≥2000 pg/ml的定义具有最高的预后准确性(AUC=0.75)。
关键数值与推荐
- 简化HFA定义:NYHA III-IV、EF<30%、12个月内≥2次心衰住院。
- GALACTIC-Severe定义:NYHA III-IV、EF<30%、6个月内≥1次住院。
- HFA定义1年心血管死亡/心衰住院风险70%、全因死亡45%(AUC=0.72)。
- GALACTIC-Severe定义1年心血管死亡/心衰住院风险59%、全因死亡38%(AUC=0.73)。
- 含NT-proBNP≥2000 pg/ml的定义AUC=0.75。
临床怎么用
- 临床可依据HFA-AdvHF定义识别更高危的HFrEF患者以尽早转诊评估高级治疗。
- GALACTIC-Severe定义可用于识别更广泛的重度心衰人群。
- 考虑将NT-proBNP、心衰住院史和利尿剂剂量纳入风险分层或试验富集策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A valid definition of severe heart failure (HF) is essential for earlier identification, timely referral for advanced therapies, and to optimize clinical trial design. OBJECTIVES: To assess the prevalence, prognostic performance, and 1-year outcomes associated with different definitions of severe and advanced HF (AdvHF) in patients with heart failure with reduced ejection fraction (HFrEF). METHODS: We included 15,153 patients with EF <40%, HF duration >6 months, and no prior left ventricular assist device or heart transplant, from the Swedish Heart Failure Registry. Several definitions of severe/AdvHF were evaluated: a simplified Heart Failure Association (HFA) definition (NYHA III-IV, EF <30%, ≥2 HF hospitalizations in 12 months), the GALACTIC-Severe-definition (NYHA III-IV, EF <30%, ≥1 hospitalization in 6 months), and variations adding/removing criteria such as NT-proBNP levels and diuretic dose to the HFA-AdvHF definition. Predictive performance and 1-year outcomes were analyzed. RESULTS: The HFA-definition identified 6.4% of patients, with a 1-year cardiovascular death/HF hospitalization risk of 70% and all-cause mortality of 45% (AUC = 0.72). The GALACTIC-Severe definition identified 12.6% of patients with slightly lower but still substantial event rates (59% and 38%, respectively; AUC = 0.73). Definitions incorporating NT-proBNP ≥2000 pg/ml had the highest prognostic accuracy (AUC = 0.75). CONCLUSIONS: The HFA-AdvHF definition selected a smaller, high-risk group, while the GALACTIC-Severe criteria identified a broader population, with a lower, but still high risk. NT-proBNP, HF hospitalization history, and diuretic dose might represent valuable enrichment tools for future trials.
引用
- Guidetti F, Lund LH, Benson L, et al. "Real-world prognostic performance of different severe and advanced heart failure definitions: Data from the Swedish Heart Failure Registry". J Heart Lung Transplant. 2026. PMID: 41862040. doi:10.1016/j.healun.2026.03.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。